Search

Displaying results 8361 - 8370 of 8553 in total
  1. Drug

    Fosgonimeton

    go.drugbank.com/drugs/DB21516
    Investigational

    Fosgonimeton has a monoisotopic molecular weight of 584.3 Da.

  2. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  3. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.

  4. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.

  5. Drug

    Nizaracianine

    go.drugbank.com/drugs/DB21517
    Investigational

    Nizaracianine has a monoisotopic molecular weight of 942.43 Da.

  6. Drug

    Clofutriben

    go.drugbank.com/drugs/DB21636
    Investigational

    Clofutriben has a monoisotopic molecular weight of 424.09 Da.

  7. Drug

    Nelutroctiv

    go.drugbank.com/drugs/DB21554
    Investigational

    Nelutroctiv has a monoisotopic molecular weight of 543.13 Da.

  8. Drug

    Biochanin A

    go.drugbank.com/drugs/DB15334
    Experimental

    Biochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).

    Categories: Estrogens, Non-Steroidal
  9. Drug

    Tifenazoxide

    go.drugbank.com/drugs/DB21402
    Investigational

    Tifenazoxide has a monoisotopic molecular weight of 290.99 Da.

  10. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to ...